Silo Pharma provides update on SPC-15 advancement, digital asset program

Silo Pharma (SILO) announced a comprehensive update detailing progress for lead candidate SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder and stress-induced anxiety, and key achievements under Silo’s new digital assets treasury platform launched in August 2025. Biopharmaceutical Platform: Silo is advancing SPC-15, its lead therapeutic candidate, through the final preparations required prior to submitting an investigational new drug application to the FDA. Recent milestones in its drug discovery program include: Positive bioanalytical and safety/toxicology results for an FDA-requested 7-day large animal safety study of SPC-15. Finalizing drug-device study of the formulation-specific microchip-based nasal spray system used for SPC-15 drug delivery. Completion of an IND-enabling GLP-compliant toxicology and toxicokinetic study of SPC-15. Data is expected in early 2026. Global intellectual property expansion with patents for SPC-15 technology in the U.S., Australia, and Japan. Continuing IP expansion is a core element of Silo’s drug development strategy. Digital Assets Treasury: Silo launched a digital assets treasury strategy in early August 2025 to participate in the growth and adoption of cryptocurrency and to expand and strengthen the Company’s capital resources. The strategy combines staking for yield with a hedged overlay to reduce volatility in portfolio positions while maintaining upside potential. Initial cryptocurrency purchases made in September and October in Bitcoin, Ethereum, Solana, and ResearchCoin. Lead crypto strategy advisor, Corwin Yu, appointed for active management of Silo’s crypto portfolio targeting multi-chain digital asset growth and decentralized finance (DeFi) integration. New Crypto Advisory Board, chaired by Corwin Yu, formed to expand Silo’s expert support for cryptocurrency audit and compliance. Two additional members are expected to join before year-end or in early 2026. Engaged Fireblocks, an enterprise platform for building blockchain applications and managing digital asset operations, and for providing custody technology services for the institutional crypto treasury platform. Set forth below are catalysts expected to further Silo’s strategies for its biopharmaceutic platform and digital asset treasury program: Data from IND-enabling GLP study is expected in 2026. Follow-up conversations with the FDA expected to occur in November 2025 to confirm what management believes are the final data points needed to open an IND before year-end for SPC-15 in PTSD. Identify, evaluate, and select clinical research organization sites for first-in-human SPC-15 trials. Pursue an additional therapeutic indication for SPC-15 to be included in human clinical trials. Secure the FDA’s 505(b)(2) accelerated regulatory pathway for clinical development. Advance SP-26 ketamine implant for chronic pain and fibromyalgia. Continue strategic purchases of various leading cryptocurrencies and optimize digital asset infrastructure and compliance platforms. Participate in the decentralized science Web3 movement, driving transparent, tokenized scientific research in collaboration with ResearchHub.